孟鲁司特治疗哮喘-慢性阻塞性肺疾病重叠综合征的效果观察

Effects of leukotriene receptor antagonists on asthma-chronic obstructive pulmonary disease overlap syndrome

目的探讨白三烯受体拮抗剂孟鲁司特治疗哮喘-慢性阻塞性肺疾病重叠综合征(ACO)的效果。方法抽取2018年1月至2020年1月威海市中心医院收治的60例ACO患者为研究对象,按照随机数字表法分为对照组和研究组,每组30例。对照组予以常规治疗,研究组在对照组治疗基础上加用孟鲁司特,记录两组治疗前后临床症状、气道炎症、肺功能等指标变化情况。结果治疗前,两组哮喘症状评分(ACT)、慢性阻塞性肺疾病症状评分(CAT)比较差异未见统计学意义(P>0.05);治疗后,两组ACT评分均较治疗前升高,CAT评分均较治疗前下降,且研究组上述评分变化幅度大于对照组(P<0.05)。治疗前,两组诱导痰中性粒细胞、嗜酸粒细胞百分比比较差异未见统计学意义(P>0.05);治疗后,两组中性粒细胞、嗜酸粒细胞百分比均较治疗前下降,且研究组上述指标变化幅度更优(P<0.05)。治疗前,两组呼气峰流速(PEF)、每分钟通气量(VE)、呼吸商(RQ)水平比较差异未见统计学意义(P>0.05);治疗后,两组PEF、VE、RQ值均较治疗前提高,且研究组上述肺功能相关指标改善幅度更优(P<0.05)。结论孟鲁司特治疗ACO患者有利于提高其临床症状、气道炎症及肺功能改善效果。

Objective To investigate the effects of leukotriene receptor antagonist montelukast in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome(ACO).Methods A total of 60 patients with ACO admitted to Weihai Central Hospital from January 2018 to January 2020 were selected as the research objects.According to the random number table method,they were divided into control group and study group,with 30 cases in each group.The control group was given routine treatment,and the study group received leukotriene receptor antagonist montelukast based on the treatment of the control group.The changes of clinical symptoms,airway inflammation,lung function and other indicators of the two groups were recorded before and after treatment.Results Before treatment,there was no significant difference in asthma control test(ACT)and chronic obstructive pulmonary disease assessment test(CAT)between the two groups(P>0.05).After treatment,the ACT scores of the two groups were higher than those before treatment,and the CAT scores were lower than those before treatment,and the change of the above scores in the study group were more significant than those in the control group(P<0.05).Before treatment,there was no significant difference in the percentage of neutrophils and eosinophils in induced sputum between the two groups(P>0.05);after treatment,the percentages of neutrophils and eosinophils in the two groups decreased,compared with those before treatment,and the changes of the above indexes in the study group were better(P<0.05).Before treatment,there was no significant difference in peak expiratory fowl rate(PEF),minute ventilation volume(VE)and respiratory quotient(RQ)between the two groups(P>0.05);after treatment,the PEF,VE and RQ of the two groups increased,compared with those before treatment,and the improvement range of lung function related indexes in the study group was better than that in the control group(P<0.05).Conclusions The application of leukotriene receptor antagonist montelukast,in the treatment of patients with ACO,is beneficial to improving its clinical symptoms,airway inflammation and lung function improvement.